Score Your Stock

US stock · figures in US dollars · scored on full-year results

Lilly (Eli) Eli Lilly and Company Common Stock

LLY · Healthcare · Drug Manufacturers - General
Top 26% of scored stocks
OkayTop 26% of scored stocks

Lilly (Eli) scores 63/100 on fundamentals: in the top 26% of 503 scored S&P 500 stocks. Its strongest area is Business Strength (100/100); its weakest is Price Fairness (33/100).

Best
Business 100
Weakest
Price 33

An expensively priced stock with healthy growth, but price fairness needs attention.

What looks good
What to watch
Mkt capUS$ 1.3t#10 of 503 in the S&P 500EPSUS$ 29.79P/E45.8×✗ vs sector median 29.6×P/B31.4×✗ vs sector median 3.7×Div yield0%Bottom 27% in the S&P 50052w range · 95% of range834.191449.68
as of 31 Oct 2026

Nearby peers

Ranks #15 of 60 in Healthcare by score

#1Universal Health Services79#13Cigna63#14Quest Diagnostics63
#15Lilly (Eli)63
#16Stryker63#17West Pharmaceutical Services63

One-Minute Summary

Why Lilly (Eli) scores 63

An expensively priced stock with healthy growth, but price fairness needs attention.

What looks good
What to watch

Business Strength

100
Why 100?
Pillar score: (2 + 2 + 2 + 2 + 2) = 10 of 10 points → 100
Return on Equity (ROE)68%Strong4-Year Revenue Growth+36%/yrStrong4-Year Profit Growth+74%/yrStrongNet Profit Margin32%StrongQuarterly Momentum+50%Strong
Show 3 charts

Net Profit & Equity, with ROE

Net Profit ↑ +426.3%Equity ↑ +273.9%ROE % 68.5%
Net ProfitEquityROE %
5.2b10.6b20.6b27.6b10.8b14.3b26.5b40.3b202320242025TTM48.6%74.2%77.8%68.5%

Revenue & Net Profit, with Net Margin

Revenue ↑ +153.4%Net Profit ↑ +426.3%Net Margin % 31.9%
RevenueNet ProfitNet Margin %
34.1b45.0b65.2b86.5b5.2b10.6b20.6b27.6b202320242025TTM15.4%23.5%31.7%31.9%

Sales grew about 153.4% over 4 years: customers keep spending more with this company.

Profit climbed about 426.3% over 4 years: the business keeps more money as it grows.

Recent Quarters: Revenue & Net Profit (the last 8 quarters, scored)

Revenue ↑ +100.8%Net Profit ↑ +631.2%Net Margin % 30.9%
RevenueNet ProfitNet Margin %
11.4b13.5b12.7b15.6b17.6b19.3b19.8b23.0b970m4.4b2.8b5.7b5.6b6.6b7.4b7.1bQ3'24Q4'24Q1'25Q2'25Q3'25Q4'25Q1'26Q2'268.5%32.6%21.7%36.4%31.7%34.4%37.4%30.9%
▲▲▲▲▲▲▲▲

Sales grew about 100.8% over the last 8 quarters: customers keep spending more with this company.

Profit grew about 631.2% over the last 8 quarters: the business is keeping more of what it earns.

Why 50?
Pillar score: (0 + 1 + 2) = 3 of 6 points → 50
Debt-to-Equity1.2×WeakCurrent Ratio1.4×OkayInterest Coverage21.8×Strong
Show 2 charts

Debt vs Equity, with D/E ratio

Total Debt ↑ +96.2%Equity ↑ +273.9%D/E 1.2×
Total DebtEquityD/E
25.2b33.6b42.5b49.5b10.8b14.3b26.5b40.3b202320242025TTM2.3×2.4×1.6×1.2×

Borrowings grew about 96.2% over 4 years: watch this; rising debt adds pressure in bad times.

Short-term assets vs bills, with Current Ratio

Current Assets ↑ +153.7%Current Liabilities ↑ +72.2%Current Ratio 1.4×
Current AssetsCurrent LiabilitiesCurrent Ratio
25.7b32.7b55.6b65.3b27.3b28.4b35.2b47.0b202320242025TTM0.9×1.2×1.6×1.4×
Why 75?
Pillar score: (0 + 2 + 2 + 2) = 6 of 8 points → 75
Dividend Quality0%Weak
Payout ratio: 22%
Operating Cash FlowPositive & growingStrongFree Cash FlowPositive & growingStrongCash & Cash EquivalentsGrowing & covers near-term debtStrong
Show 3 charts

Operating vs Free Cash Flow

Operating CF ↑ +622.8%Free CF ↑ +470.8%
Operating CFFree CF
4.2b8.8b16.8b30.6b-3.2b414m6.0b11.7b202320242025TTM

The business generates real cash, and more of it each year: a very healthy sign.

Cash vs Total Debt

Cash ↑ +73.3%Short-Term Debt ↓ -63.5%Total Debt ↑ +96.2%
CashShort-Term DebtTotal Debt
2.8b3.3b7.3b4.9b6.9b5.1b1.6b2.5b25.2b33.6b42.5b49.5b202320242025TTM

Dividends per Share, with Yield

DPS (cents) ↑ +22.4%Yield % 0.5%
DPS (cents)Yield %
9898989811313013015015015049045252060020222023202420251.6%1%0.7%0.5%

Dividends per share have been maintained or raised: management shares the rewards with you.

Why 33?
Pillar score: (0 + 0 + 2) = 2 of 6 points → 33
P/E Ratio45.8×WeakP/B Ratio31.4×WeakPEG Ratio0.6Strong
Show chart

Share Price: Weekly Closes (not part of the score)

US$ 1417.54US$ 1137.50US$ 857.45Oct '25Feb '26Jun '26Oct '26

The share price is up about 65.3% over the past year.

Why 58?
Pillar score: (2 + 0 + 2 + 0 + 1 + 2) = 7 of 12 points → 58
Earnings ConsistencySteadyStrongDebt Trend (4yr)RisingWeakShare Count Trend (4yr)-0%/yrStrongInventory vs Sales (4yr)+10.3 pp/yr vs salesWeakAsset Turnover Trend (4yr)+9.5%OkayQuarterly Consistency0 of 4 quarters downStrong
Show chart

Revenue vs Inventory, with Inventory % of Revenue

Revenue ↑ +153.4%Inventory ↑ +215.2%Inv. % of Rev. 21%
RevenueInventoryInv. % of Rev.
34.1b45.0b65.2b86.5b5.8b7.6b13.7b18.2b202320242025TTM16.9%16.8%21.1%21%
Ranks #15 of 60 in Healthcare by score

Sector peers

#1Universal Health Services79#13Cigna63#14Quest Diagnostics63
#15Lilly (Eli) (you)63
#16Stryker63#17West Pharmaceutical Services63

Full Financial History

Every reported figure behind the score, year by year. Download it, or check it against the company's own annual report.

Financial YearRevenueNet ProfitOperating Cash FlowFree Cash FlowCapExCashTotal DebtShort-Term DebtEquityCurrent AssetsCurrent LiabilitiesTotal AssetsTotal LiabilitiesInventoryDividendsReturn on Equity (ROE)Net Profit MarginDebt-to-EquityCurrent RatioInterest CoverageDividend Payout RatioDiv yieldP/E RatioP/B RatioPEG Ratio
2026US$ 86.5bUS$ 27.6bUS$ 30.6bUS$ 11.7bUS$ -19.0bUS$ 4.9bUS$ 49.5bUS$ 2.5bUS$ 40.3bUS$ 65.3bUS$ 47.0bUS$ 148.1bUS$ 107.8bUS$ 18.2b-68%32%1.2×1.4×-22%----
2025US$ 65.2bUS$ 20.6bUS$ 16.8bUS$ 6.0bUS$ -10.8bUS$ 7.3bUS$ 42.5bUS$ 1.6bUS$ 26.5bUS$ 55.6bUS$ 35.2bUS$ 112.5bUS$ 85.9bUS$ 13.7bUS$ 600.0m78%32%1.6×1.6×-26%1%46.6×36.3×1.0
2024US$ 45.0bUS$ 10.6bUS$ 8.8bUS$ 414.0mUS$ -8.4bUS$ 3.3bUS$ 33.6bUS$ 5.1bUS$ 14.3bUS$ 32.7bUS$ 28.4bUS$ 78.7bUS$ 64.4bUS$ 7.6bUS$ 520.0m74%24%2.4×1.2×21.8×44%1%65.5×48.6×2.8
2023US$ 34.1bUS$ 5.2bUS$ 4.2bUS$ -3.2bUS$ -7.4bUS$ 2.8bUS$ 25.2bUS$ 6.9bUS$ 10.8bUS$ 25.7bUS$ 27.3bUS$ 64.0bUS$ 53.1bUS$ 5.8bUS$ 452.0m49%15%2.3×0.9×21.3×78%1%98.2×47.8×-